Document Mentions (4 shared documents)

EFTA01295633_sub_001 - EFTA01295633_100

3 mentions1 same-page

Page ?Same page

doria E Participacoes Unipessoal, LDA, Plaintiff: Charles J. Potts, Mack B. Binion, LEAD ATTORNEYS, Briskm

e Court's dictate in Amgen that a court should engage the merits of a claim only to the extent necessary to verify that Rule 23 has been satisfied. Amgen, 133 S. Ct. at 1194-95. Brown I did precisely that. 1. Even evaluated in a still more painstaking manner, the workers' statistical evidence is me

its of appellants' claim at this stage would be improper." Id. at 156. Such a statement, however, is consistent with the Supreme Court's dictate in Amgen that a court should engage the merits of a claim only to the extent necessary to verify that Rule 23 has been satisfied. Amgen, 133 S. Ct. at 1194-9

EFTA00673207

2 mentions1 same-page

Page ?Same page

lody, which he had distilled from his bass heroes Charles Mingus, Scott LaFaro and others, as well as non-

approval. Regardless of the risks, many drug companies are making huge profits. Gilead, maker of Sovaldi, has profits of around 5o percent. Biogen, Amgen and other biotech firms have profits of around 30 percent. Merck and Pfizer are seeing profits of 18 percent or more. Even if profits were cut by a

EFTA02585830

2 mentions1 same-page

Page ?Same page

89ABED1E295E68FDD9790E2&gwt=pay&assetType=nyt_now&referre= 14/22 5/27/14 Can the Nervous =ystem Be Hacked? - NYTimes.com <http://NYTimes.com> the Charles =tark Draper Laboratory in Cambridge, Mass., we met with a team working on miniaturization. Draper is best known for internal navigation =ystems tha

ld me. "Sticking something on the vagus =erve to take away R.A.? People would think it's witchcraft." Zitnik's =ackground was in pharmaceuticals; at Amgen, he contributed to the development of Enbrel, a =heumatoid-arthritis drug that had $4.7 billion in sales last year, which made it No. 7 on =he indu